Skip to content

Genetic analysis and clinical validation of biomarkers in ferroptosis for atherosclerosis progression

Genetic analysis and clinical validation of biomarkers in ferroptosis for atherosclerosis progression

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061571
Enrollment
Unknown
Registered
2022-06-29
Start date
2022-06-14
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Interventions

Observation group:None

Sponsors

The Fifth Affiliated Hospital of Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Experimental group (Advanced AS): (1) 45-65 years old; (2) Patients with extracranial carotid artery plaque and carotid intima thickness >1.2mm confirmed by dual-power ultrasound examination, and able to cooperate with biological specimen sampling; (3) Informed consent was voluntarily signed before the study, and patients and/or their legal representatives were able to fully understand possible adverse reactions during the sampling process. 2. Control group (early AS): (1) 45-65 years old; (2) Patients with no plaque or stenosis in extracranial carotid artery confirmed by dual-power ultrasound, carotid intima thickness < 1.2mm, and compatible with biological specimen sampling; (3) Informed consent was voluntarily signed before the study, and patients and/or their legal representatives were able to fully understand possible adverse reactions during the sampling process.

Exclusion criteria

Exclusion criteria: 1. Patients with extracranial carotid artery dissection, extracranial carotid artery fibromuscular dysplasia, and extracranial carotid artery physiological and anatomical abnormalities; 2. Persons suffering from psychological, psychiatric, or neurological diseases; 3. Complicated with coagulopathy, active bleeding, severe infection with poor clinical control, etc.; 4. Patients who also participated in another clinical study; 5. Those who cannot cooperate with biological specimen collection; 6. Other participants judged by the investigator to be unsuitable for the clinical trial.

Design outcomes

Primary

MeasureTime frame
Expression of marker genes;

Countries

China

Contacts

Public ContactQunying Zhang

The Fifth Affiliated Hospital of Sun Yat-Sen University

zhquny@mail.sysu.edu.cn+86 13824155796

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026